Off-the-Shelf CD33 CAR-NK Cell Therapy for Relapse/Refractory AML: First-in-Human, Phase I Trial
Ruihao Huang(Army Medical University), Xi Zhang(Army Medical University), Li Gao(Army Medical University), Xiaoqi Wang(Army Medical University), Cheng Zhang(Salk Institute for Biological Studies), Xiao Han(Tencent (China)), Hongju Yan(Army Medical University), Lei Gao(Second Military Medical University), Maihong Wang(Army Medical University), Yingying Ma(Army Medical University), Qin Wen(Army Medical University)
Cited by 33
Related Papers
Recent advances in CAR-T cell engineering
|Journal of Hematology & Oncology|2020|403
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
|Cancer Cell|2020|234
TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair
|Frontiers in Oncology|2019|115
Strategies to enhance CAR-T persistence
|Biomarker Research|2022|90